{"id":"rotateq-vaccine","safety":{"commonSideEffects":[{"rate":"2-5","effect":"Diarrhea"},{"rate":"1-3","effect":"Vomiting"},{"rate":"1-2","effect":"Fever"},{"rate":"1-2","effect":"Irritability"}]},"_chembl":{"chemblId":"CHEMBL2108573","moleculeType":"Vaccine component"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"RotaTeq contains five live reassortant rotavirus strains (derived from human and bovine rotavirus parents) that replicate in the intestinal tract and trigger both humoral and mucosal immune responses. The vaccine prevents severe rotavirus gastroenteritis by inducing protective antibodies and T-cell responses against the most common rotavirus serotypes.","oneSentence":"RotaTeq is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:06:12.969Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of rotavirus gastroenteritis in infants and young children"}]},"trialDetails":[{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT06397768","phase":"PHASE3","title":"Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-05-13","conditions":"RSV Immunization","enrollment":2226},{"nctId":"NCT05794230","phase":"PHASE3","title":"Study of a Quadrivalent Meningococcal Conjugate Vaccine (MenACYW Conjugate Vaccine) Given With Routine Pediatric Vaccines in Healthy Infants and Toddlers in India and the Republic of South Africa","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2023-03-27","conditions":"Meningococcal Immunisation, Healthy Volunteers","enrollment":1528},{"nctId":"NCT06647407","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of an Investigational Pentavalent Meningococcal ABCYW Vaccine Against Meningococcal Disease in Children, Toddlers, and Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-11-05","conditions":"Meningococcal Immunization, Healthy Volunteers","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT03537508","phase":"PHASE3","title":"Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-04-25","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2627},{"nctId":"NCT04481191","phase":"PHASE3","title":"Immunogenicity and Safety of Concomitant and Non-Concomitant Administration of RotaTeq® (V260) and Inactivated Poliomyelitis Vaccine in Healthy Chinese Infants (V260-074)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2020-08-25","conditions":"Prevention of Rotavirus Gastroenteritis in Infants and Children Caused by Serotypes G1, G2, G3, G4, and G9","enrollment":400},{"nctId":"NCT03673462","phase":"PHASE3","title":"Safety of a Quadrivalent Meningococcal Conjugate Vaccine Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-09-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":2797},{"nctId":"NCT03630705","phase":"PHASE3","title":"Safety and Immunogenicity of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the Russian Federation and Mexico","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-10-17","conditions":"Healthy Volunteers (Meningococcal Infection)","enrollment":525},{"nctId":"NCT03893448","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-06-19","conditions":"Pneumococcal Infections, Pneumococcal Vaccines","enrollment":1720},{"nctId":"NCT03620162","phase":"PHASE3","title":"A Study to Evaluate the Interchangeability of V114 and Prevnar 13™ in Healthy Infants (V114-027/PNEU-DIRECTION)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2018-10-18","conditions":"Pneumococcal Infections","enrollment":900},{"nctId":"NCT01049035","phase":"PHASE2","title":"A Study of a Quadrivalent Meningococcal Tetanus Protein Conjugate Vaccine in Infants and Toddlers","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-12-16","conditions":"Meningitis, Meningococcal Infection","enrollment":580},{"nctId":"NCT00880698","phase":"PHASE2","title":"Safety and Immune Response of a Rotavirus Vaccine in HIV-infected and Uninfected Children Born to HIV-infected Mothers","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2009-12","conditions":"HIV Infection, Rotavirus Infection","enrollment":202},{"nctId":"NCT01026779","phase":"","title":"Rotavirus Gastroenteritis and Vaccine Usage in Rhode Island","status":"COMPLETED","sponsor":"Lifespan","startDate":"2009-07","conditions":"Rotavirus Gastroenteritis","enrollment":803},{"nctId":"NCT01341639","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 3, 4 and 12 Months (V419-007)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-05-26","conditions":"Bacterial Infections, Virus Diseases","enrollment":1250},{"nctId":"NCT01480258","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 in Healthy Infants When Given at 2, 4, and 11 to 12 Months (V419-008)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2011-11-23","conditions":"Bacterial Infections, Virus Diseases","enrollment":1315},{"nctId":"NCT01839188","phase":"PHASE3","title":"Spanish Mixed HEXA/PENTA/HEXA Schedule (V419-010)","status":"COMPLETED","sponsor":"MCM Vaccines B.V.","startDate":"2013-05-01","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":385},{"nctId":"NCT00875641","phase":"","title":"Safety Study of GSK Biologicals' Rotavirus Vaccine (Rotarix®) Administered to Children Aged <1 Year in the United States","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2009-04-20","conditions":"Infections, Rotavirus","enrollment":390659},{"nctId":"NCT02286895","phase":"PHASE4","title":"Immune Response to Rotavirus Vaccine After a Supplemental Dose Given at 9 Months of Age With Local EPI Vaccines in Mali","status":"COMPLETED","sponsor":"PATH","startDate":"2014-10","conditions":"Diarrhea Rotavirus","enrollment":600},{"nctId":"NCT02062385","phase":"PHASE3","title":"Efficacy, Safety, and Immunogenicity of V260 in Healthy Chinese Infants (V260-024)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2014-05-30","conditions":"Rotavirus Gastroenteritis","enrollment":4040},{"nctId":"NCT01340937","phase":"PHASE3","title":"A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-05-10","conditions":"Bacterial Infections, Virus Diseases","enrollment":2808},{"nctId":"NCT01337167","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2011-04-19","conditions":"Bacterial Infections, Virus Diseases","enrollment":1473},{"nctId":"NCT01926015","phase":"PHASE4","title":"Immunogenicity and Safety of Concomitant Administration of RotaTeq™ (V260) and the Diphtheria, Tetanus, Pertussis and Inactivated Poliovirus Vaccine (DTP-IPV) in Healthy Japanese Infants (V260-060)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-09-19","conditions":"Rotavirus Disease","enrollment":192},{"nctId":"NCT01600092","phase":"PHASE3","title":"A Study of the Immunogenicity, Tolerability, and Safety of a New Formulation of RotaTeq™ in Infants (V260-035)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2013-04-29","conditions":"Rotavirus Gastroenteritis","enrollment":1020},{"nctId":"NCT02193061","phase":"PHASE3","title":"Randomized, Controlled Single-blind Clinical Study to Assess Vaccine Interchangeability Between RV5 and RV1 Using Seven Combined Anti-rotavirus Prevention Programs","status":"COMPLETED","sponsor":"National Institute of Pediatrics, Mexico","startDate":"2013-11","conditions":"Rotavirus Vaccine","enrollment":1498},{"nctId":"NCT02847026","phase":"PHASE4","title":"Fractional Inactivated Poliovirus Vaccine Booster and Rotavirus Study","status":"COMPLETED","sponsor":"Centers for Disease Control and Prevention","startDate":"2016-09","conditions":"Poliomyelitis","enrollment":1144},{"nctId":"NCT02542462","phase":"PHASE4","title":"Potential Mechanisms for Intussusception After Rotavirus Vaccine-Pilot Study","status":"COMPLETED","sponsor":"Children's Hospital Medical Center, Cincinnati","startDate":"2015-11","conditions":"Intussusception, Rotavirus Infections","enrollment":144},{"nctId":"NCT00443846","phase":"PHASE3","title":"RotaTeq® and Meningococcus C Vaccine in Healthy Infants (V260-016)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-02-13","conditions":"Meningitis, Meningococcal, Rotavirus Infections","enrollment":247},{"nctId":"NCT01839175","phase":"PHASE3","title":"Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunisation Followed by Booster Vaccination","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-04","conditions":"Neisseria Meningitidis, Bacterial Infections, Virus Diseases","enrollment":350},{"nctId":"NCT02728869","phase":"PHASE1, PHASE2","title":"Safety, Reactogenicity and Immunogenicity of Heat-stable Rotavirus Vaccine (HSRV) in Adults and Infants","status":"COMPLETED","sponsor":"MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.","startDate":"2016-06","conditions":"Rotavirus Gastroenteritis","enrollment":100},{"nctId":"NCT01236066","phase":"","title":"Impact of Rotavirus Vaccination on Hospitalisations for Rotavirus Gastroenteritis in Children Aged <5 Years in Australia","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-10","conditions":"Rotavirus Gastroenteritis, Gastroenteritis","enrollment":1},{"nctId":"NCT01960725","phase":"PHASE4","title":"An Alternate Dosing Schedule for Pentavalent Rotavirus Vaccine (RotaTeq)","status":"COMPLETED","sponsor":"Dennis Clements","startDate":"2014-02","conditions":"Diarrhea, Gastroenteritis","enrollment":66},{"nctId":"NCT00718237","phase":"PHASE3","title":"Phase III Placebo-controlled Study of V260 (RotaTeq™) in Japanese Healthy Infants (V260-029)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-08","conditions":"Rotavirus, Gastroenteritis","enrollment":762},{"nctId":"NCT00496054","phase":"PHASE3","title":"Safety,Tolerability and Immunogenicity of Vaccination With Rotateq in Healthy Infants in India (V260-021)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2008-05","conditions":"Gastroenteritis, Rotavirus","enrollment":110},{"nctId":"NCT01074242","phase":"","title":"ROTATEQ Reexamination Study (V260-037)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-09","conditions":"Gastroenteritis Rotavirus","enrollment":3798},{"nctId":"NCT00362648","phase":"PHASE3","title":"Developing World Study for RotaTeq™ (V260-015)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2007-03","conditions":"Vomiting, Diarrhea, Fever","enrollment":7504},{"nctId":"NCT00953056","phase":"PHASE1","title":"A Study of V260 in Healthy Chinese Adults, Children and Infants (V260-028)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09","conditions":"Rotavirus Gastroenteritis","enrollment":144},{"nctId":"NCT01003431","phase":"PHASE3","title":"A Study of the Immunogenicity and Safety of Whole-Cell Pertussis Containing Vaccine Administered Concomitantly With RotaTeq™ (V260) or Rotarix™ (V260-036)(WITHDRAWN)","status":"WITHDRAWN","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-12","conditions":"Rotavirus Gastroenteritis, Diphtheria, Tetanus","enrollment":""},{"nctId":"NCT00258154","phase":"PHASE3","title":"V260 Study: Concomitant Use of V260 and INFANRIX™ Hexa in Healthy Infants (V260-010)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2006-02","conditions":"Rotavirus Disease","enrollment":403},{"nctId":"NCT00092456","phase":"PHASE3","title":"Consistency Lots Vaccine Study (V260-009)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2003-05","conditions":"Rotavirus Infections","enrollment":793},{"nctId":"NCT00090233","phase":"PHASE3","title":"Rotavirus Efficacy and Safety Trial (REST)(V260-006)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2001-01","conditions":"Rotavirus Infections","enrollment":69274},{"nctId":"NCT00092443","phase":"PHASE3","title":"Dose Confirmation Efficacy Study (V260-007)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2002-09","conditions":"Rotavirus Infections","enrollment":1312},{"nctId":"NCT00836498","phase":"PHASE1","title":"A Study of the Safety and Immune Response to RotaTeq™ Vaccine in the Elderly (V260-027)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-01","conditions":"Rotavirus","enrollment":66},{"nctId":"NCT00166517","phase":"PHASE3","title":"V260 Registration Study (V260-013)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-08","conditions":"Rotavirus","enrollment":178},{"nctId":"NCT00130832","phase":"PHASE3","title":"Concomitant Use and Staggered Use of Vaccine and Oral Poliovirus (OPV) in Healthy Infants (V260-014)(COMPLETED)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-10","conditions":"Rotavirus Infections, Gastroenteritis","enrollment":735},{"nctId":"NCT01266850","phase":"PHASE4","title":"Safety and Immunogenicity of Sequential Rotavirus Vaccine Schedules","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2011-03","conditions":"Rotavirus Infection","enrollment":1384},{"nctId":"NCT00767364","phase":"PHASE1","title":"Safety and Immunogenicity of Rotavirus Vaccine (RotaTeq(R)) in Infants With Short Bowel Syndrome","status":"COMPLETED","sponsor":"Children's Hospital of Michigan","startDate":"2009-07","conditions":"Short Bowel Syndrome","enrollment":8},{"nctId":"NCT00474526","phase":"PHASE3","title":"A Study to Evaluate Safety and Immune Response of Novartis Meningococcal ACWY Vaccine In Infants","status":"COMPLETED","sponsor":"Novartis Vaccines","startDate":"2007-03","conditions":"Meningitis, Meningococcal","enrollment":4545},{"nctId":"NCT00740935","phase":"PHASE4","title":"Impact of Systematic Infants Vaccination Against Rotavirus on Gastroenteritis Hospitalization: a Prospective Study in Brest District, France.","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2007-05","conditions":"Rotavirus Gastroenteritis","enrollment":7204}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":73,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Rotateq"],"phase":"marketed","status":"active","brandName":"Rotateq vaccine","genericName":"Rotateq vaccine","companyName":"University Hospital, Brest","companyId":"university-hospital-brest","modality":"Biologic","firstApprovalDate":"","aiSummary":"RotaTeq is a live attenuated rotavirus vaccine that stimulates the immune system to produce antibodies and cellular immunity against rotavirus infection. Used for Prevention of rotavirus gastroenteritis in infants and young children.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}